Last updated: July 16, 2026. This page tracks the FDA Pharmacy Compounding Advisory Committee's July 2026 review of seven peptide substances. It is updated as the record changes.
The short version
On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets at the agency's White Oak campus to review seven peptide substances for possible inclusion on the 503A Bulk Drug Substances List.
That is a narrower question than most of the coverage suggests. The committee is not deciding whether these peptides are approved drugs. It is not deciding whether they are legal to sell. It is advising the FDA on one specific question: whether licensed pharmacies should be permitted to compound these substances into preparations for patients who have a prescription.
The committee's vote is a recommendation. The FDA is not bound by it.
What is being reviewed, and when
Per the FDA's meeting announcement and the Federal Register notice (2026-07361), the substances are split across the two days.
July 23, 2026 — 8:00 a.m. to 4:30 p.m. ET
| Substance | Forms listed by FDA |
|---|---|
| BPC-157 | BPC-157 (free base) / BPC-157 acetate |
| KPV | KPV (free base) / KPV acetate |
| TB-500 | TB-500 (free base) / TB-500 acetate |
| MOTs-C | MOTs-C (free base) / MOTs-C acetate |
July 24, 2026 — 8:00 a.m. to 3:50 p.m. ET
| Substance | Forms listed by FDA |
|---|---|
| Emideltide (delta sleep-inducing peptide, DSIP) | Emideltide (free base) / Emideltide acetate |
| Semax | Semax (free base) / Semax acetate |
| Epitalon | Epitalon (free base) / Epitalon acetate |
Note that the FDA is reviewing each substance in both free base and acetate salt forms. This detail is routinely dropped in secondary coverage, but it matters: the listing decision applies to specified forms of a substance, not to a compound name in the abstract.
The three things people are conflating
Most of the confusion in the current news cycle comes from collapsing three separate regulatory events into one. They are not the same, and they happen independently.
1. Removal from Category 2 — completed April 2026
In April 2026, the FDA removed a group of peptides from Category 2 of its interim bulk-substances policy — the category for substances raising significant safety concerns. This was a status change, not an endorsement and not an approval. It moved these substances into a posture where they could be formally evaluated. Nothing about removal from Category 2 authorized anything.
2. The 503A compounding review — the July 2026 vote
This is what PCAC is doing on July 23–24. Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by licensed pharmacists. A substance placed on the 503A Bulks List may be compounded into a preparation for an identified patient with a valid prescription. This is a pharmacy pathway. It is not a retail pathway, not an over-the-counter pathway, and not a general authorization.
3. FDA drug approval
None of these seven substances is an FDA-approved drug. Approval requires a New Drug Application supported by adequate and well-controlled clinical investigations. No amount of PCAC activity changes that, and nothing scheduled in July 2026 puts any of these compounds on an approval track.
If you take one thing from this page: a favorable PCAC vote would not make any of these peptides an approved drug, and would not make them generally available. It would open a prescription-only compounding pathway.
What the FDA has said about the evidence
The FDA's own briefing position across all seven substances is consistent, and worth reading plainly. The agency has cited:
- The substances are not well-characterized
- There is little or no human evidence of effectiveness for the proposed routes of administration, which are mostly injectable
- There is insufficient human safety data, including unassessed immunogenicity risk — the possibility that the body mounts an immune response against the peptide
That is not a neutral framing from the agency. Anyone reading the July vote as a likely formality should weigh how the FDA has characterized the underlying evidence base.
The public docket
The public docket is FDA-2025-N-6895, at regulations.gov. The docket closes July 22, 2026 — the day before the meeting begins. After that, written comments are no longer accepted into the record for this review.
The meeting itself is open to the public, both at White Oak (10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room, Rm. 1503, Silver Spring, MD 20993) and via the FDA's online teleconference and video platform.
What comes after July
Five additional substances — GHK-Cu, Melanotan II, Dihexa, LL-37, and PEG-MGF — are scheduled for a later PCAC meeting before February 2027. The July meeting is the first of at least two review cycles, not the end of the process.
What this does not change
This review concerns pharmacy compounding. It is a separate track from research-use-only (RUO) procurement, and the outcome does not alter RUO status in either direction. Materials sold for laboratory research use are not sold for human use, are not drugs, and are outside the 503A compounding framework entirely. A yes vote does not change that. A no vote does not change that either.
VOREX supplies peptides for laboratory research use only. We are covering this proceeding because it is the most misreported story in our field right now, not because it changes what we do.
Frequently asked questions
Is BPC-157 legal now?
The April 2026 removal from Category 2 was a status change, not an authorization, and the July 2026 PCAC vote is a recommendation about pharmacy compounding — not a legalization event and not an approval. BPC-157 is not an FDA-approved drug. Material sold for laboratory research use is sold for research use only and not for human use.
Does the PCAC vote make these peptides FDA approved?
No. FDA approval requires a New Drug Application supported by adequate and well-controlled clinical investigations. The PCAC reviews whether a substance should appear on the 503A Bulk Drug Substances List for pharmacy compounding. The two processes are unrelated, and none of the seven substances is an approved drug.
What is the 503A Bulks List?
Section 503A of the Federal Food, Drug, and Cosmetic Act governs compounding by licensed pharmacists. The 503A Bulk Drug Substances List identifies bulk substances that may be used in compounding a preparation for an identified patient with a valid prescription. Placement on the list is a pharmacy pathway, not a retail or over-the-counter one.
What happened to peptides in April 2026?
The FDA removed a group of peptides from Category 2 of its interim bulk-substances policy — the category for substances raising significant safety concerns — and named seven compounds for the July 2026 PCAC review. Removal from Category 2 was a status change that allowed formal evaluation to proceed. It was not an approval or an endorsement.
When will the FDA decide?
The PCAC meets July 23–24, 2026 and votes on recommendations. The committee advises the FDA; the agency is not bound by the vote and sets its own timeline for acting on the recommendation. A further PCAC meeting covering GHK-Cu, Melanotan II, Dihexa, LL-37, and PEG-MGF is scheduled before February 2027.
Does this affect research-use-only peptides?
No. The 503A compounding framework is separate from research-use-only procurement, and the outcome of the July vote does not change RUO status in either direction. Materials supplied for laboratory research use are not drugs and are not sold for human use.
Sources
- FDA — July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee
- Federal Register — Notice of Meeting; Establishment of a Public Docket; Request for Comments (2026-07361)
- Public docket FDA-2025-N-6895, regulations.gov